Telomir Pharmaceuticals, Inc. Common Stock
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on reversing biological aging and degenerative diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Progeria, Wilson's disease, and age-related macular degeneration (amd), as well as type 2 diabetes, cancer, and Alzheimer's dis… Read more
Telomir Pharmaceuticals, Inc. Common Stock (TELO) - Total Liabilities
Latest total liabilities as of September 2025: $422.81K USD
Based on the latest financial reports, Telomir Pharmaceuticals, Inc. Common Stock (TELO) has total liabilities worth $422.81K USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Telomir Pharmaceuticals, Inc. Common Stock - Total Liabilities Trend (2021–2024)
This chart illustrates how Telomir Pharmaceuticals, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Telomir Pharmaceuticals, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Telomir Pharmaceuticals, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Beijing JIAYU Door Window Curtain
SHE:300117
|
China | CN¥2.84 Billion |
|
LabGenomics Co. Ltd
KQ:084650
|
Korea | ₩76.00 Billion |
|
Hiroca Holdings Ltd
TW:1338
|
Taiwan | NT$4.27 Billion |
|
New Delhi Television Limited
NSE:NDTV
|
India | ₹7.78 Billion |
|
TJ media Co. Ltd
KQ:032540
|
Korea | ₩42.02 Billion |
|
Big Sunshine Co Ltd
TW:1475
|
Taiwan | NT$673.04 Million |
|
DIVA Laboratories Ltd
TWO:4153
|
Taiwan | NT$422.17 Million |
|
PT Wijaya Karya (Persero) Tbk
F:5AA
|
Germany | €48.44 Trillion |
Liability Composition Analysis (2021–2024)
This chart breaks down Telomir Pharmaceuticals, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 17.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Telomir Pharmaceuticals, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Telomir Pharmaceuticals, Inc. Common Stock (2021–2024)
The table below shows the annual total liabilities of Telomir Pharmaceuticals, Inc. Common Stock from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-09-30 | $680.97K | -49.01% |
| 2023-09-30 | $1.34 Million | +35.45% |
| 2022-09-30 | $986.01K | +613.82% |
| 2021-09-30 | $138.13K | -- |